HEM Hemosense

HemoSense, Inc. (AMEX:HEM) today announced that it has received medical device licenses from Health Canada to market its INRatio� PT/INR monitoring system for point-of-care and patient self testing in Canada. HemoSense expects to formalize distribution relationships during the current fiscal quarter, and begin selling INRatio within Canada in the coming months. �We believe that entry into the Canadian market represents a significant growth opportunity with an estimated 600,000 patients on chronic warfarin therapy,� said Timothy Still, executive VP and chief commercial officer of HemoSense. �We are committed to providing convenient and easy-to-use PT/INR monitoring solutions to assist patients in managing their warfarin levels. To further strengthen our ability to expand into international markets, we received ISO 13485 certification in July of last year. ISO certification is an internationally recognized quality standard for medical devices, which is mandatory for obtaining commercial approval in a number of countries, including Canada.� Canada's health care system is a group of socialized health insurance plans that provide preventative care and medical treatment coverage to all Canadian citizens. About HemoSense HemoSense is a point-of-care diagnostic healthcare company that develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio� system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient�s warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.hemosense.com. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, the statements regarding the Company�s ability to formalize distribution relationships during the current fiscal quarter, and begin selling INRatio within Canada in the coming months are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary, expectations and are subject to risks and uncertainties which may cause the actual results to differ materially from the statements contained herein. Further information on the Company's business and risk factors are detailed in its filings with the Securities and Exchange Commission, including its 2006 Form 10-K filed on December 27, 2006. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. HemoSense� and INRatio� are registered trademarks of HemoSense, Inc.